Fig. 2From: Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case reportFirst post-treatment sellar MRI reevaluation in September 2018 demonstrating a significant volume decrease of the lesion, with a paramedian left 8 × 6 × 6 mm remnant, without alterations in the surrounding structures, in coronal (A) and lateral (B) projectionBack to article page